Drug Profile
AUTO 2
Alternative Names: AUTO2; Autologous CAR-T-cell-therapy - Autolus; Chimeric antigen receptor T-cell therapy - Autolus; SUB-96123Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Autolus
- Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 07 Dec 2019 Efficacy and adverse events data from a phase-I/II APRIL trial in Multiple myeloma presented at 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)
- 07 Nov 2019 Phase-I/II development for Multiple myeloma still ongoing in Netherlands, United Kingdom
- 25 Oct 2019 Discontinued - Phase-I/II for Multiple myeloma (Second-line therapy or greater) in Netherlands, United Kingdom (IV)